Find therapies in clinical trials near you – page 2

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Study on Ustekinumab and Guselkumab for Children with Active Juvenile Psoriatic Arthritis

Study on Ustekinumab and Guselkumab for Children with Active Juvenile Psoriatic Arthritis

Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Study on Ustekinumab and Drug Combination for Patients with Severe, Resistant Inflammatory Disease

Study on Ustekinumab and Drug Combination for Patients with Severe, Resistant Inflammatory Disease

Study on the Effects of Oxygen Therapy with Vedolizumab, Ustekinumab, or Infliximab for Adults with Moderate to Severe Ulcerative Colitis

Study on the Effects of Oxygen Therapy with Vedolizumab, Ustekinumab, or Infliximab for Adults with Moderate to Severe Ulcerative Colitis

Long-Term Study of Ustekinumab for Patients with Crohn's Disease Who Previously Lost Response to Treatment

Long-Term Study of Ustekinumab for Patients with Crohn's Disease Who Previously Lost Response to Treatment

Study on Bimekizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

Study on Bimekizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

Study on Long-term Safety of Ustekinumab for Children with Crohn's Disease, Juvenile Psoriatic Arthritis, or Ulcerative Colitis

Study on Long-term Safety of Ustekinumab for Children with Crohn's Disease, Juvenile Psoriatic Arthritis, or Ulcerative Colitis

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Study of Risankizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

Study of Risankizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

Study on Ustekinumab for Children with Moderate to Severe Ulcerative Colitis

Study on Ustekinumab for Children with Moderate to Severe Ulcerative Colitis

Study on Ustekinumab for Children with Moderate to Severe Crohn's Disease

Study on Ustekinumab for Children with Moderate to Severe Crohn's Disease